| 1.16 0.02 (1.75%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.55 |
1-year : | 1.75 |
| Resists | First : | 1.33 |
Second : | 1.5 |
| Pivot price | 1.18  |
|||
| Supports | First : | 1.05 |
Second : | 0.88 |
| MAs | MA(5) : | 1.14 |
MA(20) : | 1.19 |
| MA(100) : | 1.31 |
MA(250) : | 1.2 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 29.4 |
D(3) : | 28.6 |
| RSI | RSI(14): 47.5 |
|||
| 52-week | High : | 2 | Low : | 0.85 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NMTC ] has closed above bottom band by 36.6%. Bollinger Bands are 54.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 21 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.19 - 1.2 | 1.2 - 1.2 |
| Low: | 1.12 - 1.12 | 1.12 - 1.13 |
| Close: | 1.15 - 1.16 | 1.16 - 1.17 |
NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator for use with NeuroOne's combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. The company is based in Eden Prairie, Minnesota.
Wed, 27 Mar 2024
Where Will Neuroone Medical Technologies Corp (NMTC) Stock Go Next After It Has Gained 1.80% in a Week? - InvestorsObserver
Tue, 26 Mar 2024
NMTC Stock Quote Price and Forecast - CNN
Fri, 16 Feb 2024
NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q1 2024 Earnings Call Transcript - Yahoo Finance
Thu, 15 Feb 2024
NeuroOne: Dilution Risk Ahead (NMTC) - Seeking Alpha
Thu, 15 Feb 2024
Earnings call: NeuroOne reports progress and FDA clearance in Q1 FY2024 - Investing.com
Tue, 19 Dec 2023
NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q4 2023 Earnings Call Transcript - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 26 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 12.1 (%) |
| Held by Institutions | 25.6 (%) |
| Shares Short | 365 (K) |
| Shares Short P.Month | 144 (K) |
| EPS | -0.69 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.18 |
| Profit Margin | 0 % |
| Operating Margin | -346.8 % |
| Return on Assets (ttm) | -109.5 % |
| Return on Equity (ttm) | -214.1 % |
| Qtrly Rev. Growth | -37.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.1 |
| EBITDA (p.s.) | -0.52 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -1.71 |
| PEG Ratio | 0 |
| Price to Book value | 6.44 |
| Price to Sales | 10.66 |
| Price to Cash Flow | -2.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|